LSUHSC COBRE:POLYAMINE METABOLISM IN EBV LYMPHOMAGENESIS

LSUHSC COBRE:EBV 淋巴细胞生成中的多胺代谢

基本信息

  • 批准号:
    7610514
  • 负责人:
  • 金额:
    $ 26.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-05-01 至 2008-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Project 2-A: Analysis of Polyamine Metabolism in EBV Lymphomagenesis In the Burkitts lymphoma (BL) cell line Akata, maintenance of the malignant phenotype in vitro is dependent on retention of the EBV genome. Global gene expression analysis of paired EBV-positive and -negative Akata cell clones identified spermidine/spermine N1-acetyltransferase (SSAT) as one of a limited number of genes whose expression was significantly decreased in EBV-positive clones. SSAT is a key enzyme in the catabolism of polyamines, which are essential for cell growth. Increased polyamine levels have been detected in a number of tumors. Thus, we sought to test the hypothesis that decreased SSAT mRNA in EBV-infected cells represents viral manipulation of the polyamine metabolic pathway and a factor in EBV lymphomagenesis. We have concluded the polyamine studies, with final progress reported below. Those studies have provided the foundation for a new direction, outlined in project 2-B. Project 2-B: EBV microRNA-Mediated Epigenetic Modification of Cellular Chromatin Carcinoma cell lines infected by EBV in vitro developed subclones that lost virus but stably retained a morphological phenotypic, induced at infection, which distinguished them from the EBV-negative parental cell line. When transiently infected clones were compared by gene expression arrays to their EBV-negative parental counterparts, some 80 downregulated genes (many of which are hypermethylated in cancer) were identified in cells that had lost virus. Treatment with methyltransferase inhibitors restored the parental cell morphologic phenotype (and, in cases tested, gene expression). These preliminary observations have led us to test the hypothesis that EBV induces stable epigenetic changes that may make virus redundant with respect to continued malignant progression. Retention of a virally-induced epigenetic imprint in transiently infected cells introduces a new paradigm for how a human tumor virus might mechanistically regulate a cell in a hit-and-run fashion. We will focus on determining which EBV gene products contribute to epigenetic modification of cellular chromatin. EBV latent membrane protein 1 (LMP1) has been reported to induce DNA methyltransferase 1, 3a, and 3b and hypermethylate the E-cadherin promoter. However, the discovery of at least 17 EBV microRNAs (miRNAs), together with the ability of cellular miRNAs to target DNA for gene silencing, prompted our hypothesis that the EBV miRNAs direct methylation of specific cellular genes in a sequence specific manner. Using bioinformatic approaches, we will query which EBV miRNAs might target these cellular promoters. Transfection of the individual miRNA will provide a direct demonstration that candidate miRNAs so identified do in fact produce epigenetic silencing in EBV infection.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RONA S SCOTT其他文献

RONA S SCOTT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RONA S SCOTT', 18)}}的其他基金

Core B Modeling Core
核心 B 建模核心
  • 批准号:
    10360459
  • 财政年份:
    2021
  • 资助金额:
    $ 26.11万
  • 项目类别:
Core B Modeling Core
核心 B 建模核心
  • 批准号:
    10090770
  • 财政年份:
    2021
  • 资助金额:
    $ 26.11万
  • 项目类别:
Core B Modeling Core
核心 B 建模核心
  • 批准号:
    10569053
  • 财政年份:
    2021
  • 资助金额:
    $ 26.11万
  • 项目类别:
Epigenetic Effects of Epstein-Barr Virus Infection in Oral Squamous Cell Carcinoma
EB 病毒感染对口腔鳞状细胞癌的表观遗传效应
  • 批准号:
    8992993
  • 财政年份:
    2015
  • 资助金额:
    $ 26.11万
  • 项目类别:
LSUHSC COBRE:POLYAMINE METABOLISM IN EBV LYMPHOMAGENESIS
LSUHSC COBRE:EBV 淋巴细胞生成中的多胺代谢
  • 批准号:
    7720566
  • 财政年份:
    2008
  • 资助金额:
    $ 26.11万
  • 项目类别:
LSUHSC COBRE:POLYAMINE METABOLISM IN EBV LYMPHOMAGENESIS
LSUHSC COBRE:EBV 淋巴细胞生成中的多胺代谢
  • 批准号:
    7381981
  • 财政年份:
    2006
  • 资助金额:
    $ 26.11万
  • 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
  • 批准号:
    7617634
  • 财政年份:
    2006
  • 资助金额:
    $ 26.11万
  • 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
  • 批准号:
    7802081
  • 财政年份:
    2006
  • 资助金额:
    $ 26.11万
  • 项目类别:
LSUHSC COBRE:POLYAMINE METABOLISM IN EBV LYMPHOMAGENESIS
LSUHSC COBRE:EBV 淋巴细胞生成中的多胺代谢
  • 批准号:
    7171200
  • 财政年份:
    2005
  • 资助金额:
    $ 26.11万
  • 项目类别:
LSUHSC COBRE:POLYAMINE METABOLISM IN EBV LYMPHOMAGENESIS
LSUHSC COBRE:EBV 淋巴细胞生成中的多胺代谢
  • 批准号:
    6981874
  • 财政年份:
    2004
  • 资助金额:
    $ 26.11万
  • 项目类别:

相似海外基金

The role of the RNA helicase DDX3X in Burkitt Lymphoma and its potential as a new therapeutic target
RNA解旋酶DDX3X在伯基特淋巴瘤中的作用及其作为新治疗靶点的潜力
  • 批准号:
    461753
  • 财政年份:
    2022
  • 资助金额:
    $ 26.11万
  • 项目类别:
    Operating Grants
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10153913
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
剖析 EBV 和恶性疟原虫在地方性伯基特淋巴瘤发病机制中的作用
  • 批准号:
    10204966
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma
EB 病毒和疟疾对伯基特淋巴瘤病因学的协同作用
  • 批准号:
    10754431
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
Clonal heterogeneity and therapy resistance in Burkitt lymphoma
伯基特淋巴瘤的克隆异质性和治疗耐药性
  • 批准号:
    MR/S021590/1
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
    Fellowship
The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma
EB 病毒和疟疾对伯基特淋巴瘤病因学的协同作用
  • 批准号:
    10319534
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma
EB 病毒和疟疾对伯基特淋巴瘤病因学的协同作用
  • 批准号:
    9887039
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10924460
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
剖析 EBV 和恶性疟原虫在地方性伯基特淋巴瘤发病机制中的作用
  • 批准号:
    10671667
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
了解马拉维伯基特淋巴瘤的甲氨蝶呤剂量、药代动力学和毒性
  • 批准号:
    10397542
  • 财政年份:
    2019
  • 资助金额:
    $ 26.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了